Home » Stocks » AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

Stock Price: $4.83 USD 0.02 (0.42%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 718.32M
Revenue (ttm) 1.99B
Net Income (ttm) -17.30M
Shares Out 148.01M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE 6.36
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $4.83
Previous Close $4.81
Change ($) 0.02
Change (%) 0.42%
Day's Open 4.85
Day's Range 4.71 - 4.87
Day's Volume 627,939
52-Week Range 3.45 - 7.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

5 days ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to ...

1 week ago - Business Wire

10 Stocks to watch now trading under $10 with significant upside potential The post 10 Stocks Under $10 to Buy In July for the Rest of the Year appeared first on InvestorPlace. More From InvestorPlace S...

Other stocks mentioned: AAVVF, DTEA, EXK, GEVO, NFLX, OSS, QRHC ...
1 week ago - InvestorPlace

AMRX vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
2 weeks ago - Zacks Investment Research

The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway of the Public Health Service Act. The cover...

1 month ago - Benzinga

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologic...

1 month ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Food and Drug Administration recently accepted Amneal's 505(b)(2) New D...

1 month ago - Business Wire

If you're looking for a cheap stock to buy, check out this list of 10 highly rated picks that are priced under $10.

Other stocks mentioned: CRK, INFN, MBT, NLY, SDC, SIRI, TRUE ...
2 months ago - Kiplinger

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: RBC Globa...

2 months ago - Business Wire

AMRX vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
2 months ago - Zacks Investment Research

Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2021. “Amneal delivered solid first quarte...

2 months ago - Business Wire

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to mark...

3 months ago - Business Wire

NEW YORK, April 12, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 months ago - PRNewsWire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE: AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced that Amneal Pharmaceuticals LLC (“Amneal”), a subsidia...

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - March 31, 2021) - Levi & Korsinsky announces it has commenced an investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) concerning possible breaches of fiduciar...

3 months ago - Newsfile Corp

Investors who chase growth could be interested in the following small-cap stocks as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.

Other stocks mentioned: CXP, JKS
3 months ago - GuruFocus

Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

4 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and full year ended December 31, 2020. "We are extremely ...

4 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Company adds two directors with financial, pharmaceutical, and consumable business expertise.

Other stocks mentioned: MASS
5 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: Raymond J...

5 months ago - Business Wire

AMRX vs. CORT: Which Stock Is the Better Value Option?

Other stocks mentioned: CORT
5 months ago - Zacks Investment Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

5 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26...

5 months ago - Business Wire

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
6 months ago - Zacks Investment Research

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiG...

Other stocks mentioned: BGNE, TTOO
6 months ago - Benzinga

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under whi...

6 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated N...

6 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present at the 39...

6 months ago - Business Wire

As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to...

7 months ago - Benzinga

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, BIIB, HZNP, PAHC, SUPN
7 months ago - Investopedia

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

8 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food ...

8 months ago - Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.

8 months ago - Benzinga

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered another strong...

8 months ago - Business Wire

Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.

8 months ago - Zacks Investment Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

9 months ago - Zacks Investment Research

Is (AMRX) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to...

9 months ago - Business Wire

--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of ...

9 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equi...

9 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

10 months ago - Business Wire

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

10 months ago - Business Wire

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the d... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2002
Stock Exchange
NYSE
Ticker Symbol
AMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 6.69, which is an increase of 38.51% from the latest price.

Price Target
$6.69
(38.51% upside)
Analyst Consensus: Hold